Blood-Based Context
Plasma p-Tau217 offers a practical way to add amyloid-related biomarker information to cognitive evaluations.
FOR CLINICS AND CARE TEAMS
Add ALZ Blood Test to Your Practice
Offer a simple blood-based p-Tau217 test for patients noticing changes in memory, focus, or day-to-day function, as well as those with family history or loved ones raising concerns.
Supported by clinically validated p-Tau217 biomarker research with strong alignment to established diagnostic methods.
For clinician-directed use. Results should be interpreted within the full clinical context.
Clinical Workflow
Designed to guide decisions when concerns emerge
Blood-based p-Tau217 biomarker information adds clarity when cognitive concerns warrant further evaluation.
Why This Matters
Patients often arrive because something has changed: memory lapses, word-finding difficulty, family concern, or a family history that makes the question feel urgent. Blood-based biomarkers such as p-Tau217 add clarity when determining what to do next within a broader clinical evaluation.
Alzheimer's care is evolving quickly, with new ways to detect disease and therapies continuing to become available. Timely biomarker information makes evaluation and planning more actionable.
Traditional diagnostic pathways may involve invasive procedures or more complex access to imaging. A simple blood draw offers a more accessible entry point within a broader clinical evaluation.
At a glance
- Biomarker information helps clarify whether Alzheimer's-related changes are part of the picture.
- Blood-based testing reduces friction when cognitive concerns warrant additional context.
- Clinical interpretation remains essential for appropriate use and follow-up.
Clinical Value
ALZ Blood Test provides p-Tau217 biomarker results that complement clinical assessment and help guide next-step decisions.
PET-Aligned Performance
Supporting validation materials report approximately 95% sensitivity and specificity relative to amyloid PET-aligned reference thresholds.
Guides Next-Step Decisions
Results help determine follow-up planning, additional testing, and treatment pathways when appropriate.
Non-Invasive Workflow
A blood draw is often easier to integrate into care pathways than more invasive or complex diagnostic approaches.
- Results typically available within 1–3 days after sample processing
This test does not establish a diagnosis on its own. Results should be interpreted by a clinician alongside symptoms, history, and other relevant findings.
Designed for use within clinician-directed evaluation workflows.
When to Use
Patients Age 45+
For patients age 45+ presenting with cognitive concerns where biomarker context helps guide evaluation.
Suspected Alzheimer's Disease
When clinical presentation raises the question of Alzheimer's disease and biomarker information adds clarity.
Differential Evaluation
To help differentiate potential causes of cognitive decline within a broader workup.
Results Overview
Reports present clear interpretation categories that help clinicians frame next-step decisions.
Lower Likelihood
A negative result is associated with a lower likelihood of Alzheimer's pathology.
Consider Further Evaluation
An intermediate result signals uncertainty and should be considered alongside the full clinical picture when deciding whether additional assessment is needed.
Consistent with Amyloid Pathology
A positive result is consistent with amyloid pathology and should be reviewed within the broader clinical context.
Results should be interpreted within the full clinical context.
How It Works
The onboarding process moves clinics from registration to ordering with minimal disruption.
1
Register as a provider
Complete the registration form to begin the onboarding process for your practice.
2
Receive access credentials and ordering link
Your team receives the information needed to activate ordering and reporting access.
3
Order tests and collect samples
Collect samples in-office or use the available phlebotomy network based on your workflow.
4
Receive results through the secure reporting portal
Access completed reports through the secure reporting portal for clinician review and follow-up.
Designed to Integrate Into Your Practice
Testing fits into routine visits and standard blood draw workflows without adding operational complexity.
Simple Blood Draw
No specialized procedures required for sample collection.
Flexible Collection
Collect in-office or use a phlebotomy network based on your workflow.
Streamlined Ordering
Order and manage tests through a secure provider portal.
Clear Reporting
Receive structured results designed for clinical review and follow-up.
Why ALZ Blood Test
Designed for Clinical Usability
Built to fit real-world clinic workflows, from onboarding through result delivery.
Clear Interpretation Thresholds
Reporting is structured for consistent review of result categories.
Supports Practical Decisions
Provides biomarker context that helps inform what to do next when used with clinical judgment.
Backed by Biomarker Research
Grounded in validated p-Tau217 biomarker research and clinical performance materials.
Review Clinical Evidence and Reporting
Explore sample reports, validation data, and clinical materials to understand how results are presented and how they shape clinical next steps.
What Happens After Registration
- Access code and ordering link sent within 1-2 business days
- Account activation email for the secure provider portal
- Team follow-up if additional information is needed
- Ability to begin placing orders once activated
ALZ BLOOD TEST
Know What May Be Happening. Guide the Next Step.
Providing p-Tau217 biomarker information so clinicians can guide evaluation, follow-up, and care decisions.